Why is this company quietly announcing release date at 5.20 pm? Is there any scope? Citywire says shrewd investors in it. DYOR

The results seem promising with new patents, etc. Dr Nolan' appointment comfirms Neutec's decision to pursue Mycograb for cancer applications.

Looks like this company has a lot of potential and i'am sure that there is a potential partner in the pipeline!!!

This share is starting to really go on the recent press coverage of MSRA. Just breaking 6... Personally hoping for about 8 though.

Bit of life today :)

Positive Mycograb trial results for the treatment of Candidiasis not so long ago (20th April 06) :

Full report Link : http://www.investegate.co.uk/Article.aspx?id=200604200700527151B



Conclusions as follows:

Conclusion:

The conclusion of the paper is that "Mycograb(R) plus lipid-associated
amphotericin B produced significant clinical and culture-confirmed improvement
in outcome for patients with invasive candidiasis."

Mycograb(R) is the subject of a Common Technical Document ("CTD") for market
authorisation submitted to the EMEA in March 2005. Progress to date remains
consistent with a market launch by the end of 2006.

Prof. Arturo Casadevall from the Albert Einstein College of Medicine, New York,
said:

"Candidiasis is associated with an unacceptably high mortality rate even when
treated with antifungal drugs. Prof. Pachl's report shows that the
administration of Mycograb(R) in combination with amphotericin B to patients
with invasive candidiasis reduced candida-attributable mortality over 4-fold,
markedly improved the overall response, and increased the rate of
culture-confirmed clearance of Candida species, compared with the administration
of amphotericin B alone. This could hasten the arrival of the third-age of
antimicrobial therapy."

Prof. James Burnie, Chief Executive of NeuTec, commented:

"We are delighted that Mycograb(R) has generated so much interest and that now
the results of the pivotal trial have been published in a prestigious journal in
the field of infectious diseases. We believe that Mycograb(R) represents a new
era in the treatment of life-threatening infections. This drug reduces the
mortality of an infection which kills around 1 in 5 patients on standard
antifungal therapy. Mycograb is currently being given under a compassionate use
programme, in which it has been used in combination with either amphotericin B
or caspofungin."

Other indications:

NeuTec recently reported that patient recruitment was completed in a phase Ib
study to evaluate the safety and efficacy of Mycograb(R) in combination with
Docetaxel in metastatic or recurrent breast cancer patients. We also recently
reported that an IND in the US has been obtained for a double-blind,
placebo-controlled, multi-centre phase III study using Mycograb(R) in
combination with generic amphotericin B and 5-flucytosine against Cryptococcus
neoformans - a cause of mortality in HIV infected patients. Hospitals in the
US, South Africa and South America have agreed to take part in the study which
will commence shortly.

Someone adding to their holding with a 16K X trade at 500p mid price.

Another couple of X trades totalling 22K at mid price 500p.

Make my day !!

Lovely :)

Neutec Pharma plc
6 June 2006
For immediate release

NeuTec Pharma plc ('NeuTec' or the 'Company')

The Board of NeuTec notes the recent movement in the Company's share price. The Company is currently in discussions which may or may not lead to an offer being made for the whole of the issued and to be issued share capital of the
Company.

There can be no certainty that agreement will be reached and an offer made.

A further announcement will be made as appropriate.

In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, NeuTec
announces that it has in issue 29,058,636 ordinary shares of 25 pence each. The
International Securities Identification Number ('ISIN') for NeuTec ordinary
shares is GB0031275315.

Enquiries:

NeuTec Pharma plc
Professor James Burnie, CEO Telephone: +44 (0)161 276 8827

Going strong...........will it hit 1000p before the offer is made ? My fingers are crossed :)

Bugger, another missed ship.

KD.

A bidding war may break out? Yummy :)

"It should be relatively obviously why Neutec is attractive it's got two unpartnered relatively late stage products," the analyst told AFX News. "There are very few companies, certainly in Europe, with unpartnered late stage programmes. It wouldn't surprise me if this became a competitive bidding situation."
Devani said the suitor could be anyone from a rival biotech to large pharma. He has a 'buy' recommendation on the stock, and is advising clients to hold for now, rather than take profits..."

http://www.bloomberg.com/apps/news?pid=10000085&sid=ajerDS_qjP0U&refer=europe


Novartis Offers $569 Million to Buy NeuTec Pharma (Update1)
June 7 (Bloomberg) -- Novartis AG, Europe's third-largest drugmaker, offered to buy NeuTec Pharma Plc for 305 million pounds ($569 million) in cash to gain two experimental treatments for drug-resistant infections.

Novartis is offering 10.50 pounds per share of Neutec, the Basel, Switzerland-based company said in an e-mailed statement. NeuTec's board and shareholders with 39 percent of the company are backing the offer, according to the release.

Chief Executive Officer Daniel Vasella has been buying companies to expand the Swiss drugmaker's stable of new treatments. The company acquired Chiron Corp. and Hexal AG last year, at a time when it lacked new drugs to bolster growth.

NeuTec, based in Manchester, has two promising medicines in late stages of clinical development. One of them, Mycograb, was has been submitted to European regulators while the other, known as Aurograb, is scheduled for filing in 2010, the company said.

``Both Mycograb and Aurograb promise to dramatically improve the treatment possibilities and will enable Novartis to strengthen its biologics pipeline and anti-infective drug portfolio,'' Vasella said in the statement.



To contact the reporter on this story:
Christian Baumgaertel in Zurich at
cbaumgaertel@bloomberg.net.
Last Updated: June 7, 2006 01:41 EDT

Ok, silly question time.

Why is the price still rising when the offer is worth 1050p?

KD.

I THINK COULD BE A HIGHER BID SOON,THAT COULD BE ONE WAY OF ANSWERING YOUR QUESTION.

Hmm, I thought as much.

Thanks aeeq180

Hmm, I thought as much.

Thanks aeeq180.

KD.

Hmm, I thought as much.

Thanks aeeq180.

KD.

any time frame